People: Supernus Pharmaceuticals Inc (SUPN.W)

Summary

Name	Age	Since	Current Position
M. James Barrett	70	2005	Independent Chairman of the Board
Jack Khattar	51	2005	President, Chief Executive Officer, Director
Gregory Patrick	61	2011	Chief Financial Officer, Vice President
Stefan Schwabe	60	2012	Executive Vice-President - Research & Development, Chief Medical Officer
Padmanabh Bhatt	55	2012	Senior Vice President- Intellectual Property, Chief Scientific Officer
Victor Vaughn	55	2013	Senior Vice President - Sales
Tami Martin	57	2008	Vice President - Regulatory Affairs
Jones Bryan	48	2005	Vice President - Business Development
Michael Bigham	55	2006	Independent Director
Frederick Hudson	67	2010	Independent Director
Charles Newhall	68	2005	Independent Director
William Nuerge	60	2006	Independent Director
John Siebert	72	2011	Independent Director

» Insider Trading

Biographies

Name	Description
M. James Barrett	Dr. M. James Barrett is an Independent Chairman of the Board of Supernus Pharmaceuticals Inc., since 2005. Since September 2001, Dr. Barrett has been a general partner of New Enterprise Associates, or NEA, which is a venture capital firm that focuses on the medical and life sciences and information technology industries. He is a member of the board of directors of each of the publicly-traded companies Amicus Therapeutics, Inc. and Targacept, Inc., within the past five years, he served on the board of directors of each of the publicly-traded companies Inhibitex (acquired by Bristol-Myers Squibb Co.), Iomai Corporation (acquired by Intercell AG), MedImmune, LLC (acquired by AstraZeneca), Pharmion Corporation (acquired by Celgene Corporation) and YM Biosciences, Inc. As a result of Dr. Barrett's tenure as a general partner of New Enterprise Associates, he has served on boards of directors of both public and private companies in the healthcare sector and brings to the Board first-hand experience in shaping strategic direction as a pharmaceutical company matures from a private venture-backed company to a development-stage public company and then to a product revenue-generating company. Dr. Barrett received a Ph.D. in Biochemistry at the University of Tennessee, his MBA from the University of Santa Clara, and a BS in Chemistry from Boston College.
Jack Khattar	Mr. Jack A. Khattar is President, Chief Executive Officer, Director of Supernus Pharmaceuticals Inc., since 2005. He is the founder of the Company. From 1999 to 2005, Mr. Khattar served in positions during that time as a Board member, President and CEO of Shire Laboratories Inc., the drug delivery subsidiary of Shire plc. From 1999 to 2004, he served as a member of Shire plc's Executive Committee. Prior to that, Mr. Khattar served as an Executive Officer and the Chairman of the Management Committee at CIMA, a drug delivery company that is currently a division of Cephalon. At CIMA, he was responsible for business development, including the licensing of CIMA's technologies, corporate alliances and strategic planning. Prior to joining CIMA in 1995, Mr. Khattar held several marketing and business development positions at Merck & Co., Novartis, Playtex and Kodak in various locations, including the United States, Europe and the Middle East. Mr. Khattar earned his degrees in Marketing with a BBA from American University of Beirut and an MBA from the Wharton School of the University of Pennsylvania. He is a director of Rockville Economic Development Inc. Mr. Khattar's leadership, executive, managerial, business and pharmaceutical company experience, along with his 20 years of industry experience in the development and commercialization of pharmaceutical products and drug delivery technologies, qualify him to be a director.
Gregory Patrick	Mr. Gregory S. Patrick is Chief Financial Officer, Vice President of Supernus Pharmaceuticals Inc. Previously, he served as Chief Financial Officer for three privately held life sciences companies; R012 (2010-2011); Bionor Immuno (2008-2010); and Sopherion Therapeutics (2004-2008). From 2001 through 2004, he served as Chief Financial Officer for Medimmune, and from 1999 to 2001, as Chief Financial Officer of Ventiv Health. Mr. Patrick served in a positions at Merck & Co. from 1985 through 1999, including Vice President and Controller of Merck's Manufacturing Division, Executive Director of Corporate Planning and Reporting, and Executive Director of Financial Evaluation. He started his career with Exxon Chemical Company in engineering, and subsequently joined Booz, Allen Hamilton as a management consultant. He holds BS and ME degrees from Rensselaer Polytechnic Institute in Environmental Engineering, and an MBA in Finance from New York University.
Stefan Schwabe	Dr. Stefan K.F. Schwabe is an Executive Vice-President - Research & Development, Chief Medical Officer of Supernus Pharmaceuticals, Inc., since July 9, 2012. Prior to that, Dr. Schwabe served as Chief Operating Officer at DemeRx, a privately-held biotech company, working in the area of addiction. From 2006 through 2010, Dr. Schwabe was the Vice-President for Project Direction for Neurology Projects at Sanofi-Aventis, and from 2004 through 2006, he served as the Executive Director, US Clinical Development and Medical Affairs, Neuroscience for Novartis. From 1998 through 2004, Dr. Schwabe served as the Global Project Leader — Topamax for Johnson & Johnson. Prior to that time, Dr. Schwabe held positions of Medical Director, Gabitril & Seroxat in the Health Care Strategy Unit, International Operations for Novo Nordisk, and both International Project Team Leader and International Clinical Team Leader — Trileptal and Scientific Investigator for Ciba-Geigy. Dr. Schwabe received his Bachelor Science in Chemistry from Florida International University, his M.D. from the Ludwig-Maximilians University in Munich, Germany and his Ph.D./Doctorate from the Department of Toxicology at the Technical University of Munich, Germany. Dr. Schwabe served as Chief Resident, Department of Neurology for the Medical College of Wisconsin in Milwaukee, Wisconsin.
Padmanabh Bhatt	Dr. Padmanabh P. Bhatt is Senior Vice President- Intellectual Property, Chief Scientific Officer of Supernus Pharmaceuticals Inc., since March 2012. Prior to that, he served as Vice President of Pharmaceutical Sciences since 2005. From 2003 to 2005, Dr. Bhatt was Vice President of Advanced Drug Delivery at Shire Laboratories Inc. From 2001 to 2003, Dr. Bhatt served as Vice President of Research and Development and Chief Technology Officer at Point Biomedical Corporation. From 1996 to 2001, he served at ALZA Corporation (now a Johnson & Johnson company) in positions from Product Development Manager to Director of Technical Development. Prior to that time, Dr. Bhatt has held positions as Research Specialist and Group Leader of Novel Drug Delivery at Dow Corning Corporation (from 1992 to 1996) and Senior Scientist at Hercon Laboratories (from 1989 to 1992). Dr. Bhatt earned his B.Pharm. and M.Pharm. degrees from the University of Bombay, India. He holds M.S. and Ph.D. degrees in Pharmaceutical Chemistry from the University of Kansas.
Victor Vaughn	Mr. Victor Vaughn is appointed as the Senior Vice President - Sales of Supernus Pharmaceuticals, Inc. He owned and operated Mt. Zion Consulting, a consulting firm that worked with small to medium sized pharmaceutical companies, assisting them with their commercial operations. From 1992 to 2005, Mr. Vaughn led the sales organization at Shire Pharmaceuticals, where he last served as Senior Vice President of Sales. Prior to that he held various positions in sales and sales management at Fujisawa and SmithKline Beecham (Glaxo). Mr. Vaughn holds a Bachelors Degree in Business Administration from East Tennessee State University.
Tami Martin	Ms. Tami T. Martin is Vice President - Regulatory Affairs of Supernus Pharmaceuticals Inc., since 2008. She has previously held positions as Vice President of Regulatory Affairs at Shire Pharmaceuticals (6 years), and Manager to Sr. Director of Regulatory Affairs at Otsuka America Pharmaceuticals (7 years). Ms. Martin has consulted privately for domestic and international clients as President and CEO of Pyramid Regulatory Consulting. Earlier in her career, Ms. Martin held legal positions at Hogan & Hartson as a member of the Food and Drug Practice Group, and with the Department of Health and Human Services as a staff attorney. Ms. Martin previously served as an instructor for the Johns Hopkins University Masters of Biotechnology and Regulatory Affairs Graduate Degree program, and teaches a portion of the United States Regulatory Module for TOPRA (The Organization for Professionals in Regulatory Affairs) to a MSc in Regulatory Affairs through the University of Wales. Ms. Martin earned her Bachelor of Science in Nursing from Albright College and a Juris Doctorate degree from Suffolk University. Ms. Martin is a member of the Pennsylvania Bar.
Jones Bryan	Dr. Jones W. Bryan is Vice President - Business Development of Supernus Pharmaceuticals Inc., since 2005. From 2000 to 2005, he served as Vice President Business Development for Shire Laboratories Inc. Prior to that, Dr. Bryan was Director of Business Development for Pharmaceutics and Clinical Supply Manufacturing for AAI. He began his career with Schering Plough in Pharmaceutics and Formulation Development. Dr. Bryan earned his B.S. degree in Zoology from Clemson University, Ph.D. degree in Pharmaceutics from the Medical University of South Carolina and Executive Management Certificate from the University of North Carolina Kenan-Flagler Business School. He is a member of the Licensing Executives Society and serves on Clemson University's Spiro Institute Entrepreneurship Advisory Board.
Michael Bigham	Mr. Michael F. Bigham is an Independent Director of Supernus Pharmaceuticals Inc., since 2006. Since 2002, Mr. Bigham has been a general partner of Abingworth, a international venture capital firm concentrating in life sciences. From December 2002 to March 2004, he served as Vice Chairman of Corixa Corporation, and was President and Chief Executive of Coulter Pharmaceuticals from July 1996 until it merged into Corixa in December 2000. Previously, he was an early employee at Gilead Sciences where he spent eight years serving in capacities, including Executive Vice President of Operations and Chief Financial Officer. Before joining Gilead, Mr. Bigham was a partner at Hambrecht & Quist where he became Co-Head of Healthcare Investment Banking. He currently chairs the compensation committee of the board of directors of Avila Therapeutics, Inc. and he previously chaired the audit committee of the board of directors of Valeritas, Inc. He is also a director of Secure EDI Holdings, Inc. He has previously served as a director of Hydra Biosciences, Inc., Magellan Inc., PrimeraDx, Inc., Xenogen Corporation and SED, Inc. Prior to February 23, 2009, Mr. Bigham was a non-executive director of Dynogen Pharmaceuticals Inc., a private clinical stage pharmaceutical company that, on that date, filed a voluntary petition for relief under Chapter 7 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Massachusetts. Mr. Bigham earned his B.S. Degree with distinction from the University of Virginia and holds an MBA from Stanford University Graduate School of Business. Mr. Bigham is a Certified Public Accountant.
Frederick Hudson	Mr. Frederick M. Hudson is an Independent Director of Supernus Pharmaceuticals Inc., since 2010. Mr. Hudson retired as a partner in charge of the health care audit practice for the Washington - Baltimore business unit of the accounting firm of KPMG, LLP on January 1, 2006 after a 37-year career with the firm. He is a graduate of Loyola University Maryland and serves in a board capacity with the Board of Financial Administration of the Catholic Archdiocese of Baltimore and the Board of Trustees of the Maryland Historical Society. He chairs the audit committees of each of the boards of directors of Educate, Inc. and GBMC Healthcare, Inc. and its affiliate, Greater Baltimore Medical Center. He is a director of Maxim Health Care Services, Inc. Mr. Hudson received a B.S. in Accounting from Loyola University, Maryland. Mr. Hudson's accounting and health care audit experience qualify him to serve as a director.
Charles Newhall	Mr. Charles W. Newhall is an Independent Director of Supernus Pharmaceuticals Inc., since 2005. 1977, Mr. Newhall co-founded NEA, a venture capital firm that focuses on the medical and life sciences and information technology industries. To date, Mr. Newhall has served as a director of over 40 venture-backed companies. He started several healthcare information technology companies like PatientKeeper, TargetRx and LifeMetrix. Some of his board memberships include Vitae Pharmaceuticals, TargetRx, Sensors for Medicine and Science, and BrainCells Inc. In 1986, he founded the Mid-Atlantic Venture Capital Association, or MAVA, which now has 80 venture capital firms that are members, and is one of the active regional venture associations in the country. He is Chairman Emeritus of MAVA. Before NEA, Mr. Newhall was a Vice President of T. Rowe Price. He served in Vietnam commanding an independent platoon including an initial reconnaissance of Hamburger Hill. His decorations include the Silver Star and Bronze Star V (1st OLC). He earned an Honors Degree in English from the University of Pennsylvania and an MBA from Harvard Business School. Mr. Newhall's experience with companies in the healthcare sector and his venture capital, financial and business experience qualify him to serve as a director.
William Nuerge	Mr. William A. Nuerge is an Independent Director of Supernus Pharmaceuticals Inc., since 2006. Since 2007, Mr. Nuerge has been a managing partner of Fortress Pharms Advisors, LLC. From 2004 to 2007, Mr. Nuerge served as a director and President and CEO of Xanodyne Pharmaceuticals. From 1997 to 2004, he served as President and CEO of Shire US, Inc. Prior to that, Mr. Nuerge served as Chief Operating Officer of Richwood Pharmaceuticals Company, Inc., which merged with Shire plc in 1997. Mr. Nuerge earned his Bachelor of Science degree from Purdue University and his MBA from Wesleyan University. Mr. Nuerge's operational and business experience with life science companies qualify him to serve as a director.
John Siebert	Dr. John M. Siebert is an Independent Director of Supernus Pharmaceuticals Inc., since 2011. Dr. Siebert has 30 years experience in the pharmaceutical industry. Since 2011, Dr. Siebert has been Chief Operating Officer of New Rhein Healthcare Investors, LLC, a healthcare-based private equity group. Since 2009, Dr. Siebert has been Chairman and CEO of Compan Pharmaceuticals, LLC, a veterinary specialty pharmaceutical company. From 2004 to 2009, Dr. Siebert served as Chairman and CEO at CyDex Pharmaceuticals Inc., a specialty pharmaceutical company. From 1995 through 2003, Dr. Siebert served as President and CEO of CIMA LABS, Inc., an innovative oral drug delivery company. Dr. Siebert started his career at Procter & Gamble. He chairs the audit committee of the board of directors of Aradigm, Inc. He is a member of the Board of Directors of Accu-Break Pharmaceuticals, Inc. Dr. Siebert's operational and business experience with companies in the healthcare sector, combined with his scientific experience, qualify him to serve as a director.

Basic Compensation

Name	Fiscal Year Total
M. James Barrett	--
Jack Khattar	599,691
Gregory Patrick	424,544
Stefan Schwabe	--
Padmanabh Bhatt	354,016
Victor Vaughn	--
Tami Martin	--
Jones Bryan	278,250
Michael Bigham	--
Frederick Hudson	--
Charles Newhall	--
William Nuerge	--
John Siebert	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
M. James Barrett	0	0
Jack Khattar	0	0
Gregory Patrick	0	0
Stefan Schwabe	0	0
Padmanabh Bhatt	0	0
Victor Vaughn	0	0
Tami Martin	0	0
Jones Bryan	65,500	251,520
Michael Bigham	0	0
Frederick Hudson	0	0
Charles Newhall	0	0
William Nuerge	0	0
John Siebert	0	0

Insider Trading

Name	Shares Traded	Price
BIGHAM MICHAEL F	15,000	$5.65
SIEBERT JOHN M	3,000	$5.50
BIGHAM MICHAEL F	5,000	$5.20
BIGHAM MICHAEL F	10,000	$5.26
BIGHAM MICHAEL F	5,000	$5.17
KHATTAR JACK A	10,000	$6.15
PATRICK GREGORY S	5,000	$6.95
ORBIMED ADVISORS L L C	41,100	$7.58
ORBIMED ADVISORS L L C	108,900	$7.58
ORBIMED ADVISORS L L C	110,700	$7.52
ORBIMED ADVISORS L L C	41,483	$7.52
BHATT PADMANABH P	25,000	$0.40
ORBIMED ADVISORS L L C	100,000	$7.08
ORBIMED ADVISORS L L C	197,815	$6.85
SIEBERT JOHN M	2,188	$4.24
MARTIN TAMI TILLOTSON	9,375	$2.56
MARTIN TAMI TILLOTSON	1,250	$3.36
MARTIN TAMI TILLOTSON	37,500	$1.60
SIEBERT JOHN M	7,000	$8.14
BHATT PADMANABH P	25,000	$0.40
HUDSON FREDERICK M	5,000	$5.00
NEWHALL CHARLES W III	4,400,000	$5.00
KHATTAR JACK A	5,000	$5.00
ORBIMED ADVISORS L L C	734,128	$5.00
BARRETT MICHAEL JAMES	4,400,000	$5.00

» Full list on Insider Trading

People: Supernus Pharmaceuticals Inc (SUPN.W)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: